5 completed, 3 terminated, 1 recruiting. 9 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 5, Terminated 3, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow Idiopathic Interstitial Pneumonias: new trials by email Literature Review of Idiopathic Interstitial Pneumonias trials Research Report on Idiopathic Interstitial Pneumonias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis Zinc, Placebos for zinc and nicotinamide riboside, Nicotinamide riboside - Idiopathic Pulmonary Fibrosis | Phase 2 | Recruiting | Cedars-Sinai Medical Center | 60 | 2025-11-03 | 2025-11-10 |
| A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis BMS-986278 Placebo, BMS-986278 - Pulmonary Fibrosis | Phase 2 | Completed | Bristol-Myers Squibb | 403 | 2020-07-29 | 2026-02-03 |
| A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis CC-90001, Placebo - Idiopathic Pulmonary Fibrosis, Fibrosis | Phase 2 | Terminated | Celgene | 138 | 2017-07-26 | 2023-06-28 |
| A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis Belumosudil, BSC - Idiopathic Pulmonary Fibrosis | Phase 2 | Completed | Kadmon Corporation, LLC | 76 | 2016-05-26 | 2022-09-08 |
| Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP) Riociguat (Adempas, BAY63-2521), Placebo - Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary | Phase 2 | Terminated | Bayer | 147 | 2014-06-04 | 2017-12-04 |
| Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT Bardoxolone methyl, Placebo - Pulmonary Arterial Hypertension, Pulmonary Hypertension | Phase 2 | Completed | Biogen | 166 | 2014-05-31 | 2025-06-10 |
| Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF) Pamrevlumab, Placebo, Sub-Study: Pirfenidone - Idiopathic Pulmonary Fibrosis | Phase 2 | Completed | Kyntra Bio | 160 | 2013-07-30 | 2020-09-04 |
| Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease Bone marrow mesenchymal stem cells, Placebo - Idiopathic Interstitial Pneumonia, Interstitial Lung Disease | Phase 1 / Phase 2 | Completed | Federal Research Clinical Center of Federal Medical & Biological Agency, Russia | 20 | 2013-02-01 | 2018-01-09 |
| Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant Prednisone, Azithromycin, Montelukast - Respiratory Tract Infections, Bronchiolitis Obliterans | Phase 2 | Terminated | Maisonneuve-Rosemont Hospital | 12 | 2011-09-01 | 2021-10-20 |
Idiopathic Pulmonary Fibrosis (7) · Lung Diseases, Interstitial (6) · Pulmonary Fibrosis (5) · Cryptogenic Organizing Pneumonia (2) · Fibrosis (2) · Lung Diseases (2) · Bronchiolitis Obliterans (1) · Hamman-Rich Syndrome (1) · Hypertension (1) · Hypertension, Pulmonary (1) · Interstitial Pneumonitis, Desquamative, Familial (1) · Pathologic Processes (1) · Pulmonary Arterial Hypertension (1) · Pulmonary Disease, Chronic Obstructive (1)
Respiratory Tract Diseases (8) · Lung Diseases (7) · Pathological Conditions, Signs and Symptoms (6) · Pathologic Processes (5) · Pulmonary Fibrosis (4) · Fibrosis (3) · Lung Diseases, Interstitial (3) · Bronchial Diseases (2) · Bronchiolitis (2) · Bronchitis (2) · Cardiovascular Diseases (2) · Idiopathic Pulmonary Fibrosis (2) · Lung Diseases, Obstructive (2) · Organizing Pneumonia (2) · Vascular Diseases (2)
Azithromycin (1) · Budesonide (1) · Budesonide, Formoterol Fumarate Drug Combination (1) · CC-90001 (1) · Formoterol Fumarate (1) · Immunoglobulin G (1) · KD025 (1) · ORF 50 transactivator (1) · Prednisone (1) · Steroids (1) · Zinc (1) · bardoxolone methyl (1) · belumosudil (1) · montelukast (1) · nicotinamide-beta-riboside (1)
Bayer (1) · Biogen (1) · Bristol-Myers Squibb (1) · Cedars-Sinai Medical Center (1) · Celgene (1) · Federal Research Clinical Center of Federal Medical & Biological Agency, Russia (1) · Kadmon Corporation, LLC (1) · Kyntra Bio (1) · Maisonneuve-Rosemont Hospital (1)
United States (7) · Canada (5) · Australia (4) · Germany (4) · Russia (3) · United Kingdom (3) · Argentina (2) · Belgium (2) · Brazil (2) · Colombia (2) · France (2) · Greece (2) · Israel (2) · Italy (2) · Japan (2)
Anish Ambaram, M.D. (1) · Benedict Brockway, M.D. (1) · Bhanu Singh, M.D. (1) · Catherina Chang, M.D. (1) · Danielle Antin-Ozerkis, M.D. (1) · Danielle D. Hosmer (1) · David Lederer, M.D. (1) · Elizabeth F Krakow, MD,CM, FRCPC (1) · Elizabeth Veitch, M.D. (1) · Elvis Irusen, M.D. (1) · Evans R Fernandez-Perez, M.D (1) · Heidi Siebert, M.D. (1) · Huw Davies, M.D. (1)
PMID 31416769, PMID 31575509, PMID 34709814, PMID 34894681, PMID 34969771, PMID 35058236, PMID 38484130, PMID 39393084, PMID 40210090, PMID 40355288
2016 (1), 2019 (1)